Restoration of desmosomal junction protein expression and inhibition of H3K9‑specific histone demethylase activity by cytostatic proline‑rich polypeptide‑1 leads to suppression of tumorigenic potential in human chondrosarcoma cells

Galoian,Karina; Qureshi,Amir; Wideroff,Gina; Temple,H. T.

doi:10.3892/mco.2014.445

Restoration of desmosomal junction protein expression and inhibition of H3K9‑specific histone demethylase activity by cytostatic proline‑rich polypeptide‑1 leads to suppression of tumorigenic potential in human chondrosarcoma cells

Authors:
- Karina Galoian
- Amir Qureshi
- Gina Wideroff
- H. T. Temple
View Affiliations

Affiliations: Department of Orthopaedic Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USA, University of Miami Tissue Bank Division, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
Published online on: October 16, 2014 https://doi.org/10.3892/mco.2014.445
Pages: 171-178

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Disruption of cell‑cell junctions and the concomitant loss of polarity, downregulation of tumor‑suppressive adherens junctions and desmosomes represent hallmark phenotypes for several different cancer cells. Moreover, a variety of evidence supports the argument that these two common phenotypes of cancer cells directly contribute to tumorigenesis. In this study, we aimed to determine the status of intercellular junction proteins expression in JJ012 human malignant chondrosarcoma cells and investigate the effect of the antitumorigenic cytokine, proline‑rich polypeptide‑1 (PRP‑1) on their expression. The cell junction pathway array data indicated downregulation of desmosomal proteins, such as desmoglein (1,428‑fold), desmoplakin (620‑fold) and plakoglobin (442‑fold). The tight junction proteins claudin 11 and E‑cadherin were also downregulated (399‑ and 52‑fold, respectively). Among the upregulated proteins were the characteristic for tumors gap junction β‑5 protein (connexin 31.1) and the pro‑inflammatory pathway protein intercellular adhesion molecule (upregulated 129‑ and 43‑fold, respectively). We demonstrated that PRP‑1 restored the expression of the abovementioned downregulated in chondrosarcoma desmosomal proteins. PRP‑1 inhibited H3K9‑specific histone demethylase activity in chondrosarcoma cells in a dose‑dependent manner (0.5 µg/ml PRP, 63%; 1 µg/ml PRP, 74%; and 10 µg/ml PRP, 91% inhibition). Members of the H3K9 family were shown to transcriptionally repress tumor suppressor genes and contribute to cancer progression. Our experimental data indicated that PRP‑1 restores tumor suppressor desmosomal protein expression in JJ012 human chondrosarcoma cells and inhibits H3K9 demethylase activity, contributing to the suppression of tumorigenic potential in chondrosarcoma cells.

View Figures

View References

1	Fitzgerald MP, Gourronc F, Teoh ML, et al: Human chondrosarcoma cells acquire an epithelial-like gene expression pattern via an epigenetic switch: evidence for mesenchymal-epithelial transition during sarcomagenesis. Sarcoma. 2011(598218)2011. View Article : Google Scholar
2	Yang J, Du X, Wang G, et al: Mesenchymal to epithelial transition in sarcomas. Eur J Cancer. 50:593–601. 2014. View Article : Google Scholar : PubMed/NCBI
3	Wells A, Yates C and Shepard CR: E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis. 25:621–628. 2008. View Article : Google Scholar : PubMed/NCBI
4	Wiles ET, Bell R, Thomas D, Beckerle M and Lessnick SL: ZEB2 represses the epithelial phenotype and facilitates metastasis in Ewing sarcoma. Genes Cancer. 4:486–500. 2013. View Article : Google Scholar
5	Latorre IJ, Frese KK and Javier RT: Tigh. junction proteins and cancer. Tight Junctions. Gonzalez-Mariscal L: Springer US; New York, NY: pp. 116–134. 2006, View Article : Google Scholar
6	Chipman JK, Mally A and Edwards GO: Disruption of gap junctions in toxicity and carcinogenicity. Toxicol Sci. 71:146–153. 2003. View Article : Google Scholar : PubMed/NCBI
7	Gill GA, Buda A, Moorghen M, et al: Characterisation of adherens and tight junctional molecules in normal animal larynx; determining a suitable model for studying molecular abnormalities in human laryngopharyngeal reflux. J Clin Pathol. 58:1265–1270. 2005. View Article : Google Scholar
8	Kolegraff K, Nava P, Helms MN, et al: Loss of desmocollin-2 confers a tumorigenic phenotype to colonic epithelial cells through activation of Akt/β-catenin signaling. Mol Biol Cell. 22:1121–1134. 2011.PubMed/NCBI
9	Yang L, Chen Y, Cui T, et al: Desmoplakin acts as a tumor suppressor by inhibition of the Wnt/β-catenin signaling pathway in human lung cancer. Carcinogenesis. 33:1863–1870. 2012.PubMed/NCBI
10	Holen I, Whitworth J, Nutter F, et al: Loss of plakoglobin promotes decreased cell-cell contact, increased invasion and breast cancer cell dissemination in vivo. Breast Cancer Res. 14:R862012. View Article : Google Scholar : PubMed/NCBI
11	Yashiro M, Nishioka N and Hirakawa K: Decreased expression of the adhesion molecule desmoglein-2 is associated with diffuse-type gastric carcinoma. Eur J Cancer. 42:2397–2403. 2006. View Article : Google Scholar : PubMed/NCBI
12	Leithe E, Sirnes S, Omori Y, et al: Downregulation of gap junctions in cancer cells. Crit Rev Oncog. 12:225–256. 2006. View Article : Google Scholar : PubMed/NCBI
13	Galoian K, Scully S, McNamara G, et al: Antitumorigenic effect of brain proline rich polypeptide-1 in human chondrosarcoma. Neurochem Res. 34:2117–2121. 2009. View Article : Google Scholar : PubMed/NCBI
14	Galoian K, Temple TH and Galoyan A: Cytostatic effect of the hypothalamic cytokine PRP-1 is mediated by mTOR and cMyc inhibition in high grade chondrosarcoma. Neurochem Res. 36:812–818. 2011. View Article : Google Scholar : PubMed/NCBI
15	Galoian KA, Temple TH and Galoyan A: Cytostatic effect of novel mTOR inhibitor, PRP-1 (galarmin) in MDA 231 (ER-) breast carcinoma cell line. PRP-1 inhibits mesenchymal tumors. Tumour Biol. 32:745–751. 2011. View Article : Google Scholar : PubMed/NCBI
16	Galoian K, Temple TH and Galoyan A: mTORC1 inhibition and ECM-cell adhesion-independent drug resistance via PI3K-AKT and PI3K-RAS-MAPK feedback loops. Tumour Biol. 33:885–890. 2012. View Article : Google Scholar : PubMed/NCBI
17	Galoyan AA and Aprikyan VS: A new hypothalamic polypeptide is a regulator of myelopoiesis. Neurochem Res. 27:305–312. 2002. View Article : Google Scholar : PubMed/NCBI
18	Galoyan A: Neurochemistry of brain neuroendocrine immune system: signal molecules. Neurochem Res. 25:1343–1355. 2000. View Article : Google Scholar : PubMed/NCBI
19	Silberberg M, Charron AJ, Bacallao R, et al: Mispolarization of desmosomal proteins and altered intercellular adhesion in autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol. 288:F1153–F1163. 2005. View Article : Google Scholar : PubMed/NCBI
20	Delker DA, McGettigan BM, Kanth P, Pop S, Neklason DW, Bronner MP, Burt RW and Hagedorn CH: RN. sequencing of sessile serrated colon polyps identifies differentially expressed genes and immunohistochemical markers. PLoS One. 9:e883672014. View Article : Google Scholar
21	Rosette C, Roth RB, Oeth P, et al: Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis. 26:943–950. 2005. View Article : Google Scholar : PubMed/NCBI
22	Chun MG and Hanahan D: Genetic deletion of the desmosomal component desmoplakin promotes tumor microinvasion in a mouse model of pancreatic neuroendocrine carcinogenesis. PLoS Genet. 6:e10011202010. View Article : Google Scholar
23	Dusek RL and Attardi LD: Desmosomes: new perpetrators in tumour suppression. Nat Rev Cancer. 11:317–323. 2011. View Article : Google Scholar : PubMed/NCBI
24	Chidgey M and Dawson C: Desmosomes: a role in cancer? Br J Cancer. 96:1783–1787. 2007. View Article : Google Scholar
25	Delva E, Tucker DK and Kowalczyk AP: The desmosome. Cold Spring Harb Perspect Biol. 1:a0025432009. View Article : Google Scholar : PubMed/NCBI
26	Green KJ and Gaudry CA: Are desmosomes more than tethers for intermediate filaments? Nat Rev Mol Cell Biol. 1:208–216. 2000. View Article : Google Scholar : PubMed/NCBI
27	Rieger-Christ KM, Ng L, Hanley RS, et al: Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential. Br J Cancer. 92:2153–2159. 2005. View Article : Google Scholar : PubMed/NCBI
28	Simcha I, Geiger B, Yehuda-Levenberg S, et al: Suppression of tumorigenicity by plakoglobin: an augmenting effect of N-cadherin. J Cell Biol. 133:199–209. 1996. View Article : Google Scholar : PubMed/NCBI
29	Aktary Z and Pasdar M: Plakoglobin: role in tumorigenesis and metastasis. Int J Cell Biol. 2012(189521)2012. View Article : Google Scholar
30	Yin T, Getsios S, Caldelari R, et al: Plakoglobin supresses keratinocyte motility through both cell-cell adhesion-dependent and -independent mechanisms. Proc Natl Acad Sci USA. 102:5420–5425. 2005. View Article : Google Scholar : PubMed/NCBI
31	Tam LW and Weinberg RA: The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med. 19:1438–1449. 2013. View Article : Google Scholar : PubMed/NCBI
32	Shi L, Sun L, Li Q, et al: Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc Natl Acad Sci USA. 108:7541–7546. 2011. View Article : Google Scholar : PubMed/NCBI
33	Kirmizis A, Bartley SM, Kuzmichev A, Margueron R, et al: Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev. 18:1592–1605. 2004. View Article : Google Scholar : PubMed/NCBI
34	Li LL, Xue AM, Li BX, et al: JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI. Breast Cancer Res. 16:R562014. View Article : Google Scholar : PubMed/NCBI
35	Kogure M, Takawa M, Cho HS, et al: Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition. Cancer Lett. 336:76–84. 2013. View Article : Google Scholar : PubMed/NCBI